Peptides vs Ozempic for Weight Loss
What You Need to Know
Disclosure: peptides.io earns affiliate commissions from some telehealth providers listed below. This does not affect our editorial ratings or recommendations.
The Short Answer
Ozempic (semaglutide) is itself a peptide. It belongs to a class called GLP-1 receptor agonists, which are synthetic peptides that mimic a hormone your gut produces after eating.
When people search “peptides vs Ozempic,” they usually mean one of two things. Either they want to compare FDA-approved GLP-1 drugs like Ozempic against other peptide therapies. Or they want to know whether Ozempic is a peptide at all.
The answer to both: yes, Ozempic is a peptide. And yes, there are meaningful differences between GLP-1 peptides and other peptide categories used for weight management.
This article breaks down every option with clinical data, costs, and access paths. Use it to make an informed choice with your doctor.
What are Peptides, and Why Do They Matter for Weight Loss?
Peptides are short chains of amino acids. Your body produces thousands of them naturally. They act as signaling molecules, telling cells what to do: release hormones, regulate appetite, repair tissue, or manage blood sugar.
In medicine, synthetic peptides are designed to mimic or enhance these natural signals. For weight loss, the most studied peptides fall into three groups.
GLP-1 receptor agonists copy a gut hormone called glucagon-like peptide-1. They suppress appetite, slow stomach emptying, and improve insulin sensitivity. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the most prescribed examples.
Growth hormone secretagogues stimulate your pituitary gland to release more growth hormone. Sermorelin and tesamorelin are the two with FDA-recognized pathways. They support body composition changes over months, not rapid weight loss.
Research-stage peptides include compounds like AOD-9604 and retatrutide. Some show promise in clinical trials but are not yet FDA-approved for weight loss.
Ozempic is a Peptide: Here is Why That Matters
Semaglutide, the active ingredient in Ozempic and Wegovy, is a 31-amino-acid peptide. Novo Nordisk engineered it to resist breakdown in the body. One weekly injection maintains therapeutic levels for seven days.
This matters because the “peptides vs Ozempic” framing creates a false divide. Ozempic does not sit outside the peptide category. It sits at the top of it, backed by more clinical trial data than any other weight loss peptide.
The more useful comparison is between peptide categories: FDA-approved GLP-1s, prescription GH peptides, and research-stage compounds. Each has different evidence levels, safety profiles, costs, and regulatory status.
FDA-approved GLP-1 Peptides for Weight Loss
Three GLP-1 peptide medications currently hold FDA approval for weight management. A fourth (retatrutide) is in late-stage trials.
Semaglutide (Wegovy)
Semaglutide received FDA approval for chronic weight management in June 2021. In the STEP 1 trial, participants taking 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks. The placebo group lost 2.4%.
Semaglutide also carries an FDA-approved indication for cardiovascular risk reduction in adults with obesity (approved March 2024, SELECT trial).
Brand names: Wegovy (weight loss), Ozempic (type 2 diabetes), Rybelsus (oral tablet for diabetes)
Tirzepatide (Zepbound)
Tirzepatide works on two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism produced the strongest weight loss results of any approved medication.
In the SURMOUNT-1 trial, participants on the highest dose (15 mg) lost an average of 22.5% of their body weight over 72 weeks. The 10 mg dose produced 19.5% loss, and the 5 mg dose produced 15%.
Brand names: Zepbound (weight loss), Mounjaro (type 2 diabetes)
Liraglutide (Saxenda)
Liraglutide was the first GLP-1 approved for weight management (2014). It requires daily injections and produces more modest results. In the SCALE trial, participants lost approximately 8% of their body weight over 56 weeks.
Liraglutide remains an option for patients who cannot tolerate semaglutide or tirzepatide. It is no longer first-line for most prescribers.
Brand names: Saxenda (weight loss), Victoza (type 2 diabetes)
Comparison table: FDA-approved GLP-1 peptides
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Liraglutide (Saxenda) |
|---|---|---|---|
| Average weight loss | 14.9% (68 weeks) | 15-22.5% (72 weeks) | ~8% (56 weeks) |
| Mechanism | GLP-1 agonist | Dual GIP/GLP-1 agonist | GLP-1 agonist |
| Dosing frequency | Once weekly | Once weekly | Once daily |
| Administration | Subcutaneous injection | Subcutaneous injection | Subcutaneous injection |
| Oral option available | Yes (Rybelsus, for diabetes only) | In development | No |
| List price per month | ~$1,349 | ~$1,060 | ~$1,350 |
| FDA approval year | 2021 | 2023 | 2014 |
| CV risk reduction data | Yes (SELECT trial) | In progress | No |
Other Peptides Used for Weight Loss
Beyond GLP-1 agonists, several other peptide types are marketed or discussed for weight management. The evidence base varies significantly.
Growth hormone secretagogues
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates your pituitary gland to produce more growth hormone naturally, rather than injecting GH directly. Sermorelin is legally available through licensed compounding pharmacies with a prescription.
Sermorelin does not produce the rapid, dramatic weight loss that GLP-1 medications deliver. It supports gradual improvements in body composition (more lean mass, less fat mass) over three to six months. Some research suggests it may improve sleep quality and recovery.
Sermorelin costs $150 to $300 per month through a compounding pharmacy. This is significantly less than brand-name GLP-1 medications.
Tesamorelin (Egrifta) holds FDA approval for reducing abdominal fat in adults with HIV-associated lipodystrophy. It is a GHRH analog similar to sermorelin. Some providers prescribe it off-label for body composition in non-HIV patients, though this use is not FDA-approved.
Research-stage compounds
Retatrutide is a triple-action peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. In Phase 3 trials, participants on the highest dose lost 28.7% of their body weight over 68 weeks. If approved, retatrutide would produce the strongest weight loss results of any medication to date. It does not yet have an FDA-approved indication.
AOD-9604 is a modified fragment of human growth hormone. It was studied for fat metabolism in the early 2000s but failed to win FDA approval. AOD-9604 is not FDA-approved for any use in the United States. Some clinics still offer it, but the evidence supporting its weight loss claims is thin compared to GLP-1 data.
Important regulatory note
Several peptides popular in wellness communities are classified as FDA Category 2 bulk substances. These include BPC-157, ipamorelin, and CJC-1295. This means they cannot legally be compounded by pharmacies for human use as of early 2026. An FDA reclassification announcement in February 2026 may return some of these compounds to Category 1 status, but the official updated list has not been published yet. None of these compounds have strong clinical evidence for weight loss specifically.
Peptides vs Ozempic: Side-by-side Comparison
| Factor | GLP-1 peptides (Ozempic, Zepbound) | Growth hormone peptides (sermorelin) | Research compounds (AOD-9604) |
|---|---|---|---|
| Weight loss evidence | Strong (Phase 3 RCTs, 14.9-22.5%) | Limited (body composition studies) | Weak (failed Phase 2) |
| FDA-approved for weight loss | Yes | No (approved for other uses) | No |
| Mechanism | Appetite suppression, insulin regulation | Stimulates natural GH release | Modified GH fragment |
| Time to see results | 4-8 weeks | 3-6 months | Uncertain |
| Monthly cost (brand) | $1,000-$1,350 | $150-$300 | Varies (unregulated) |
| Monthly cost (compounded) | $200-$500 | $150-$300 | N/A |
| Prescription required | Yes | Yes | Should be, but often sold without |
| GI side effects | Common (nausea, constipation) | Uncommon | Uncommon |
| Long-term safety data | Yes (5+ years) | Moderate | Minimal |
Side Effects: GLP-1 Peptides vs Other Peptide Therapies
GLP-1 side effects
The most common side effects of semaglutide and tirzepatide are gastrointestinal. Nausea affects 40 to 44% of patients in clinical trials. Vomiting occurs in 15 to 25%. Diarrhea and constipation each affect 15 to 30%.
These side effects are most pronounced during the dose-escalation phase (the first 8 to 16 weeks) and tend to decrease over time. Most patients describe them as mild to moderate.
Rare but serious risks include pancreatitis and gallbladder disease. Semaglutide also carries a boxed warning about medullary thyroid carcinoma risk. This warning is based on rodent studies and has not been confirmed in humans.
A PubMed review of GLP-1 agonist trials found that semaglutide’s superior weight loss was independent of gastrointestinal adverse events. In other words, patients who experienced less nausea still lost significant weight.
Growth hormone peptide side effects
Sermorelin and tesamorelin side effects are generally milder. The most commonly reported effects are injection site reactions (redness, swelling), headache, and flushing.
Growth hormone peptides carry a contraindication for patients with active cancer or a history of certain cancers. GH can promote cell growth, which is beneficial for healthy tissue but potentially harmful in the presence of malignancy. Your prescriber should screen for this before starting therapy.
Key takeaways: side effects
GLP-1 peptides cause more GI side effects but have the strongest safety monitoring data (100,000+ trial participants across the class). Side effects usually improve after the first 8 to 16 weeks.
Growth hormone peptides cause fewer day-to-day side effects but carry a cancer screening requirement. Long-term safety data is thinner than GLP-1 data.
Unregulated peptides from online vendors carry unknown risks because manufacturing quality, purity, and dosing accuracy are not guaranteed.
Cost Comparison in 2026
Cost is often the deciding factor. Here is what you can expect to pay for each peptide category.
Brand-name GLP-1 medications
Wegovy (semaglutide) lists at approximately $1,349 per month. Zepbound (tirzepatide) lists at approximately $1,060 per month. Saxenda (liraglutide) lists at approximately $1,350 per month.
Insurance coverage varies. Many employer plans now cover GLP-1 medications for BMI 30+ (or BMI 27+ with a comorbidity). Medicare Part D began covering some GLP-1 medications for obesity in 2026. Check your specific plan.
Compounded semaglutide
Compounded versions of semaglutide are available through licensed 503A and 503B pharmacies at $200 to $500 per month. The FDA has issued safety warnings about some compounded products, particularly those from unverified sources. If you pursue compounded semaglutide, verify that the pharmacy holds current state and federal licenses.
Growth hormone peptides
Sermorelin costs $150 to $300 per month through a licensed compounding pharmacy. Tesamorelin (Egrifta) costs $800 to $1,200 per month at list price, though it is typically covered by insurance for its approved HIV-lipodystrophy indication.
What is not included in these costs
All prescription peptide therapies require a medical consultation. Telehealth consultations for GLP-1 prescriptions typically cost $0 to $50. Lab work (metabolic panel, A1C) may add $50 to $200 if not covered by insurance.
How to Decide Which Peptide Therapy is Right for You
Your choice depends on your primary goal, budget, and medical history.
If your goal is significant weight loss (15%+ of body weight): FDA-approved GLP-1 peptides are the evidence-backed choice. Tirzepatide (Zepbound) produces the strongest average results. Semaglutide (Wegovy) has the longest track record and cardiovascular data.
If your goal is modest body recomposition (more muscle, less fat): Growth hormone peptides like sermorelin may be a fit, especially if you are already exercising regularly and want support with recovery and lean mass. Expect gradual changes over months, not weeks.
If you cannot tolerate GLP-1 side effects: Talk to your provider about slower dose titration, switching between semaglutide and tirzepatide, or whether a GH peptide approach makes sense for your situation.
If cost is the primary barrier: Compounded semaglutide ($200 to $500/month) or sermorelin ($150 to $300/month) cost significantly less than brand-name GLP-1 medications. Verify pharmacy licensing before purchasing compounded products.
How to Get a Prescription Safely
All FDA-approved peptide therapies for weight loss require a prescription from a licensed medical provider. Several telehealth platforms now offer consultations and prescriptions for GLP-1 medications.
Refills.com offers GLP-1 consultations with licensed providers, including semaglutide and tirzepatide programs. The platform handles prescribing, pharmacy coordination, and ongoing monitoring in one place.
When evaluating any telehealth provider for peptide therapy, look for these four things:
- A licensed prescriber (MD, DO, NP, or PA) reviews your medical history before prescribing.
- The pharmacy dispensing your medication holds current state and federal licenses.
- The program includes follow-up check-ins, not just an initial prescription.
- The provider will not prescribe without reviewing lab work (metabolic panel at minimum).
Avoid any source that sells injectable peptides without a prescription. This applies to “research chemical” vendors and overseas pharmacies. Product quality, sterility, and dosing accuracy cannot be verified from these sources.
Frequently Asked Questions
Is Ozempic a peptide?
Yes. Semaglutide, the active ingredient in Ozempic and Wegovy, is a synthetic peptide with 31 amino acids. It belongs to the GLP-1 receptor agonist class, which are all peptide-based medications. The question “peptides vs Ozempic” is slightly misleading because Ozempic is itself a peptide therapy.
What peptide works like Ozempic?
Tirzepatide (Mounjaro, Zepbound) is the closest alternative. It targets the same GLP-1 receptor plus a second receptor called GIP. In clinical trials, tirzepatide produced greater average weight loss than semaglutide. Liraglutide (Saxenda) is an older GLP-1 peptide with more modest results.
Are peptides safer than Ozempic?
It depends on which peptides you mean. Growth hormone peptides like sermorelin cause fewer GI side effects than semaglutide. But semaglutide has been studied in over 100,000 clinical trial participants, giving it the most thoroughly studied safety profile of any weight loss peptide (100,000+ trial participants). Unregulated peptides from online vendors carry unknown safety risks.
Can you take peptides and Ozempic together?
Some providers combine GLP-1 therapy with growth hormone peptides like sermorelin. There is limited published data on this specific combination, so safety profiles for paired use are not well established. Always disclose all medications and supplements to your prescribing provider before combining therapies. Your provider can monitor for interactions.
How much weight can you lose with peptides?
Results vary by compound. Semaglutide (Wegovy) produces 14.9% average body weight loss over 68 weeks. Tirzepatide (Zepbound) produces 15 to 22.5% over 72 weeks. Growth hormone peptides like sermorelin do not produce significant scale weight loss but may improve body composition over three to six months.
What is the best alternative to Ozempic for weight loss?
Tirzepatide (Zepbound) is the strongest FDA-approved alternative. It produced greater average weight loss than semaglutide in head-to-head trials. For patients who cannot access or afford GLP-1 medications, sermorelin is a lower-cost prescription peptide option, though it works through a different mechanism and produces more modest body composition changes.
Are compounded peptides safe?
Compounded semaglutide from licensed 503A and 503B pharmacies can be a legitimate, lower-cost option. The FDA has warned about fraudulent compounded products with falsified labels. Verify your pharmacy’s licenses through your state board of pharmacy. Never purchase injectable peptides from unlicensed online vendors.
What peptides are FDA-approved for weight loss?
As of April 2026, three peptide medications hold FDA approval for chronic weight management: semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda). Retatrutide is in Phase 3 clinical trials and may become the fourth approved option. No other peptide category (growth hormone peptides, research compounds) holds FDA approval specifically for weight loss.
This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Individual results vary based on medical history, dosage, and lifestyle factors.
peptides.io is part of the Medaly longevity discovery platform. Some links in this article are affiliate links. We may earn a commission if you use them to access telehealth services. This does not affect our editorial independence or the accuracy of our content.